Get the Stockscreener App
43.33
1.07%
-0.47
After Hours:
43.34
0.01
+0.02%
Avidity Biosciences Inc stock is traded at $43.33, with a volume of 708.61K.
It is down -1.07% in the last 24 hours and down -3.95% over the past month.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
See More
Previous Close:
$43.80
Open:
$43.99
24h Volume:
708.61K
Relative Volume:
0.60
Market Cap:
$5.13B
Revenue:
$10.60M
Net Income/Loss:
$-252.45M
P/E Ratio:
-13.98
EPS:
-3.1
Net Cash Flow:
$-158.91M
1W Performance:
-0.73%
1M Performance:
-3.95%
6M Performance:
+57.85%
1Y Performance:
+603.41%
1-Day Range:
$42.63
$44.52
1-Week Range:
$41.75
$45.98
52-Week Range:
$6.60
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
43.33 | 5.13B | 10.60M | -252.45M | -158.91M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Dyne, Avidity initiated at outperform by RBC on DM1 drugs (NASDAQ:DYN) - Seeking Alpha
Avidity Biosciences to Present at Evercore ISI HealthCONx Conference | RNA Stock News - StockTitan
Avidity Biosciences to Participate in Upcoming Investor Conference - Nasdaq
Royal Bank of Canada Begins Coverage on Avidity Biosciences (NASDAQ:RNA) - MarketBeat
RBC Capital initiates Avidity Biosciences shares with Outperform rating By Investing.com - Investing.com UK
Intech Investment Management LLC Makes New $1.70 Million Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Holdings Boosted by Victory Capital Management Inc. - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Has $9.97 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Awards $43.65 Stock Options, RSUs to New Employees | RNA Stock News - StockTitan
Avidity Biosciences director Arthur Levin sells $139,972 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences director Arthur Levin sells $139,972 in stock - Investing.com India
Avidity Biosciences' chief HR officer Teresa McCarthy sells $1.03m in stock - Investing.com Canada
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for - MSN
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News - MSN
Mutual of America Capital Management LLC Sells 19,252 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Research Analysts Set Expectations for RNA FY2024 Earnings - MarketBeat
Los Angeles Capital Management LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
State of New Jersey Common Pension Fund D Buys Shares of 44,898 Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
12,319 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Purchased by Assetmark Inc. - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Shares Down 7.8%Time to Sell? - MarketBeat
RA Capital Management's Strategic Acquisition in Avidity Bioscie - GuruFocus.com
Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc - GuruFocus.com
Avidity Biosciences unveils new cardiology development candidates - BioWorld Online
RNA Stock Hits Record High on Entering the Cardiac Disease Space - Yahoo Finance
US Bancorp DE Cuts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences stock soars to all-time high of $50.86 By Investing.com - Investing.com Canada
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 - Quantisnow
Avidity Biosciences stock soars to all-time high of $50.86 - Investing.com
Avidity Biosciences jumps 16%; reaches all-time high (RNA:NASDAQ) - Seeking Alpha
Avidity Biosciences (NASDAQ:RNA) Reaches New 1-Year HighShould You Buy? - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Assessing Avidity Biosciences: Insights From 10 Financial Analysts - Benzinga
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PR Newswire
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights - GuruFocus.com
Avidity Biosciences (RNA) Stock Surges On Positive AOC 1020 Trial Results - Barchart
Avidity Biosciences' SWOT analysis: RNA stock poised for growth in precision cardiology - Investing.com
Avidity Biosciences Unveils Advances in Cardiology Research - TipRanks
Avidity Biosciences, Inc. Announces AOC 1072 and AOC 1086 as Initial Precision Cardiology Development Candidates and Shared First Look At Its Next-Generation Technology Innovations - Marketscreener.com
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations - Quantisnow
Selling US$1.0m Of Avidity Biosciences Stock Rewarded Insiders - Simply Wall St
Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Canada Finance
431,210 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Fiera Capital Corp - MarketBeat
Avidity Biosciences CFO sells $4.8 million in stock - Investing.com India
Avidity Biosciences CFO sells $4.8 million in stock By Investing.com - Investing.com Canada
Wellington Management Group LLP's Strategic Acquisition in Avidi - GuruFocus.com
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights - BioSpace
Avidity Biosciences Reports Strong Q3 Progress and Outlook - TipRanks
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates - MSN
Avidity Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avidity Biosciences Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCarthy Teresa | Chief Human Resources Officer |
Nov 18 '24 |
Sale |
41.14 |
25,000 |
1,028,520 |
94,018 |
| LEVIN ARTHUR A | Director |
Nov 19 '24 |
Option Exercise |
1.24 |
3,323 |
4,121 |
18,153 |
| LEVIN ARTHUR A | Director |
Nov 19 '24 |
Sale |
42.12 |
3,323 |
139,973 |
14,830 |
| MacLean Michael F | Chief Financial Officer |
Nov 06 '24 |
Option Exercise |
8.43 |
79,057 |
666,064 |
159,275 |
| MacLean Michael F | Chief Financial Officer |
Nov 06 '24 |
Sale |
45.56 |
106,319 |
4,843,979 |
94,093 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):